MOR MorphoSys AG ADRs

MorphoSys AG engages in the development of therapeutic antibodies to cure inflammatory and autoimmune diseases, as well as cancer and infectious diseases. The company operates through two business segments; Partnered Discovery and Proprietary Development. This is an ADR of a company whose stock trades outside of the U.S. as the symbol GF:MOR.

$11.38  -0.39 (-3.31%)
As of 10/27/2021 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Germany
Country of incorporation:  
IPO date:  04/19/2018
Outstanding shares:  136,927,772
Average volume:  52,132
Market cap:   $1,611,639,876
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    617760202
ISIN:        US6177602025
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.48
PS ratio:   9.69
Return on equity:   -16.89%
Net income %:   -70.81%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy